Gsk (GSK) Short-term Investments (2009 - 2026)

Gsk (GSK) has 18 years of Short-term Investments data on file, last reported at $123.4 million in Q2 2026.

• For the quarter ending Q2 2026, Short-term Investments fell 53.74% year-over-year to $123.4 million; the trailing twelve-month figure through Jun 2026 stood at $123.4 million (down 53.74% YoY), and the FY2025 full-year result was $161.0 million, up 165.58% from the prior year.
• Short-term Investments was $123.4 million for Q2 2026 at Gsk, up from -$258.9 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $313.1 million in Q3 2024 to a low of -$383.0 million in Q3 2022.
• A 5-year average of $44.7 million and a median of $127.8 million in 2022 frame the typical range for Short-term Investments.
• Across the five-year window, Short-term Investments jumped 529.07% in 2023 and tumbled 316.33% in 2026, its largest moves.
• Gsk's Short-term Investments stood at $222.9 million in 2022, then retreated by 27.6% to $161.3 million in 2023, then plunged by 252.73% to -$246.4 million in 2024, then surged by 165.31% to $161.0 million in 2025, then retreated by 23.31% to $123.4 million in 2026.
• Per Business Quant data, the three most recent Short-term Investments figures were $123.4 million in Q2 2026, -$258.9 million in Q1 2026, and $161.0 million in Q4 2025.